POINT Biopharma Global Inc., (PNT): Price and Financial Metrics

POINT Biopharma Global Inc., (PNT): $12.50

0.02 (+0.16%)

POWR Rating

Component Grades

Momentum

F

Stability

D

Sentiment

Quality

C

Add PNT to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#98 of 356

in industry

PNT Price/Volume Stats

Current price $12.50 52-week high $14.35
Prev. close $12.48 52-week low $6.57
Day low $12.49 Volume 3,290,900
Day high $12.51 Avg. volume 1,442,213
50-day MA $13.22 Dividend yield N/A
200-day MA $9.79 Market Cap 1.33B

PNT Stock Price Chart Interactive Chart >


POINT Biopharma Global Inc., (PNT) Company Bio


POINT Biopharma Global Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of radioligand therapies for the treatment of cancer. Its products include PNT2001, a PSMA radioligand that is in preclinical studies for early stage prostate cancer treatment; PNT2002, which is in Phase 3 studies to evaluate superiority to the standard of care in mCRPC patients; PNT2003, a somatostatin-targeted radioligand therapy that is in Phase 3 trials for the treatment of patients with somatostatin receptor-positive neuroendocrine tumors; and PNT2004, a radioligand that targets fibroblast activation protein-a. The company is based in Indianapolis, Indiana.


PNT Latest News Stream


Event/Time News Detail
Loading, please wait...

PNT Latest Social Stream


Loading social stream, please wait...

View Full PNT Social Stream

Latest PNT News From Around the Web

Below are the latest news stories about POINT BIOPHARMA GLOBAL INC that investors may wish to consider to help them evaluate PNT as an investment opportunity.

Lilly Completes Acquisition of POINT Biopharma

Eli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of POINT Biopharma Global Inc. (NASDAQ: PNT), a radiopharmaceutical company with a pipeline of clinical and preclinical-stage radioligand therapies in development for the treatment of cancer.

Yahoo | December 27, 2023

Lantheus and POINT Biopharma Announce Positive Topline Results from Pivotal SPLASH Trial in Metastatic Castration-Resistant Prostate Cancer

Phase 3 SPLASH study of 177Lu-PNT2002 demonstrated statistically significant improvement in radiographic progression-free survival (rPFS)BEDFORD, Mass. and INDIANAPOLIS, Dec. 18, 2023 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (Lantheus) (NASDAQ: LNTH) and POINT Biopharma Global Inc. (POINT) (NASDAQ: PNT) today announced statistically significant topline results from the pivotal phase 3 SPLASH study evaluating the efficacy and safety of 177Lu-PNT2002, a prostate-specific membrane antigen (PSMA)

Yahoo | December 18, 2023

Lilly Extends Tender Offer to Acquire POINT Biopharma to Dec. 22, 2023

Eli Lilly and Company (NYSE: LLY) today announced the extension of the expiration of the tender offer to acquire all of the issued and outstanding shares ("Shares") of common stock of POINT Biopharma Global Inc. (NASDAQ: PNT), for a purchase price of $12.50 per share in cash, without interest and less any applicable tax withholding.

Yahoo | December 18, 2023

Lilly Extends Tender Offer to Acquire POINT Biopharma to Dec. 15, 2023

Eli Lilly and Company (NYSE: LLY) today announced the extension of the expiration of the tender offer to acquire all of the issued and outstanding shares ("Shares") of common stock of POINT Biopharma Global Inc. (NASDAQ: PNT), for a purchase price of $12.50 per share in cash, without interest and less any applicable tax withholding.

Yahoo | December 4, 2023

Lilly Extends Tender Offer to Acquire POINT Biopharma to Dec. 1, 2023

Eli Lilly and Company (NYSE: LLY) today announced the extension of the expiration of the tender offer to acquire all of the issued and outstanding shares ("Shares") of common stock of POINT Biopharma Global Inc. (NASDAQ: PNT), for a purchase price of $12.50 per share in cash, without interest and less any applicable tax withholding.

Yahoo | November 17, 2023

Read More 'PNT' Stories Here

PNT Price Returns

1-mo N/A
3-mo N/A
6-mo -9.42%
1-year 34.84%
3-year N/A
5-year N/A
YTD N/A
2023 0.00%
2022 30.18%
2021 -59.77%
2020 N/A
2019 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!